is a strategic partner for Small and Mid – Capitalization US Biopharmaceutical companies and other US organizations executing clinical studies delivering FDA quality and cost-efficient exploratory clinical trials for NCEs, 505(b)2 compounds and clinical end-point trials for generics which are executed along the US-India corridor.
provide its clients with a high value added resource optimization solution that is currently leveraged by large Pharma and Biotech companies. PreKlin strives to provide clients with quality that matches US client expectations and that meets USFDA standards.
Resource optimization is the key for resource constrained small cap and mid cap healthcare companies and non-profit organizations. PreKlin believes that R&D costs can be dramatically decreased and development time lines accelerated by using its high impact off-shoring strategy. Hence resource constrained sponsors can stretch their R&D budgets and accelerate their development timelines to maximize value of their pipeline within budgetary constraints.
